Clinical Trial Detail

NCT ID NCT03567720
Title Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OncoSec Medical Incorporated
Indications

triple-receptor negative breast cancer

Therapies

Pembrolizumab + Tavokinogene telseplasmid

Nab-paclitaxel + Pembrolizumab + Tavokinogene telseplasmid

Age Groups: adult senior

No variant requirements are available.